CellaVision AB (publ) (LON:0MR5)

London flag London · Delayed Price · Currency is GBP · Price in SEK
187.70
-8.70 (-4.43%)
At close: Feb 20, 2025
-24.77%
Market Cap 329.73M
Revenue (ttm) 52.20M
Net Income (ttm) 10.16M
Shares Out n/a
EPS (ttm) 0.43
PE Ratio 32.47
Forward PE n/a
Dividend 0.17 (0.09%)
Ex-Dividend Date May 7, 2025
Volume 178
Average Volume 169
Open 188.80
Previous Close 196.40
Day's Range 188.20 - 188.80
52-Week Range 13.40 - 21.16
Beta 1.23
RSI 32.60
Earnings Date Feb 6, 2025

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers ... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 1994
Employees 228
Stock Exchange London Stock Exchange
Ticker Symbol 0MR5
Full Company Profile

Financial Performance

In 2024, CellaVision AB's revenue was 723.22 million, an increase of 6.78% compared to the previous year's 677.29 million. Earnings were 140.72 million, an increase of 7.99%.

Financial numbers in SEK Financial Statements

News

There is no news available yet.